Compare Tencent Music Entertainment Group - ADR (TME) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tencent Music Entertainment Group - ADR vs Vertex Pharmaceuticals Incorporated — how do they compare? Tencent Music Entertainment Group - ADR trades at $7.96 (market cap $13.50B), while Vertex Pharmaceuticals Incorporated trades at $521.58 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9.9× Tencent Music Entertainment Group - ADR's market cap, and Tencent Music Entertainment Group - ADR pays a 2.98% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| TME | VRTX | |
|---|---|---|
Market Cap | $13.50B | $134.06B |
Sector | Media | Health |
52-Week High | $26.36 | $557.96 |
52-Week Low | $7.89 | $376.62 |
Enterprise Value | $11.44B | $128.18B |
Dividend Yield | 2.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tencent Music Entertainment (TME) trades at $8.06, down 2.42% on the day, with technical indicators signaling a bearish trend. The company reported strong Q2 2026 earnings with an EPS beat of $0.25 versus $0.24 expected, and revenue growth to $32.9B in 2025. However, recent news highlights a $1 billion notes offering and mixed analyst sentiment amid competitive pressures.
TME presents a value opportunity with a low P/E of 9.46 and a consensus price target of $12.15, but faces risks from slowing growth and intense competition. Investors should weigh solid fundamentals against near-term headwinds in the music streaming sector.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
